Alex Biese

From the benefits of early adoption to the effectiveness of telehealth, here is what we reported about palliative care throughout the year.

This marks the second FDA approval of Tevimbra this year.

An expert spoke with CURE® about the importance of information that can be gained from genetic testing for patients with breast cancer.

The treatment combination was found to reduce the risk of follicular lymphoma progression or death by 57%, a study has shown.

With breakthroughs from melanoma to pancreatic cancer, this has been a year of great promise in the field of cancer vaccines.

After sharing his cancer story online, Jace Yawnick is in a state of technical remission after receiving a diagnosis of non-Hodgkin lymphoma at age 25.

The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who progressed on/after chemotherapy.

From a Pro Football Hall of Famer announcing his diagnosis to an R&B star’s latest update, here’s what’s happening in the cancer space this week.

CURE® spoke with an expert about follicular lymphoma, a disease that is still considered incurable.

The Food and Drug Administration has approved Ensacove for patients with ALK-positive locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK-inhibitor.

An expert advises a few things to keep in mind when patients with cancer are navigating these platforms.

An expert explained the impact that burnout can have on someone caring for a loved one with cancer.

Caregivers shouldn’t hesitate to ask for help when it comes to coordinating care for a loved one.

From counseling services to wellness workshops, there is a wide array of resources potentially available to caregivers, as an expert explained.

An expert explained that improved communication will make caregivers of loved ones with cancer feel less isolated.

Black patients may be more affected by certain side effects from Talvey compared with White patients with multiple myeloma, an expert told CURE®.

CAN-2409 resulted in disease-free survival improvements for patients with high-risk, localized prostate cancer.

Patients with locally advanced gastric cancers saw complete response rates of 18.3% from camrelizumab and rivoceranib plus chemotherapy.

From Gerry Turner announcing he has cancer to the return of a Chicago Cubs legend’s disease, here’s what’s happening in the cancer space this week.

Findings from the phase 1 SERENA-1 study were presented at the 2024 San Antonio Breast Cancer Symposium.

From a Hollywood star sharing an uplifting update to the death of a three-time boxing champion, here’s what’s happening in the cancer space this week.

With more than 150 treatments being studied in clinical trials, what is on the horizon for antibody-drug conjugates in breast cancer?

Author and kidney cancer survivor Katie Coleman explains why patients with cancer need to advocate for themselves when navigating the medical system.

The novel treatment is being evaluated for patients with previously treated transfusion-dependent lower-risk myelodysplastic syndrome.

The FDA has approved the first systemic therapy for patients with NSCLC or pancreatic adenocarcinoma with an NRG1 gene fusion.

An expert from the CURE® advisory board explains the likely treatability of Dave Coulier’s non-Hodgkin lymphoma.

The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic nonsquamous NSCLC with EGFR mutations.

Singer-songwriter Danielia Cotton, a thyroid cancer survivor and marathon runner shared how her experiences impact her art.

Researchers have found an increased frequency of severe maternal morbidity and obstetric complications among women who received a diagnosis of a hematological malignancy during pregnancy.

Musician Danielia Cotton and her partner, attorney Sam Roberts, discuss how much they’ve shared with their daughter about their cancer journeys.